InCarda Logo.png
InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020
13 nov. 2020 10h00 HE | InCarda Therapeutics, Inc.
Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of...
InCarda Logo.png
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
21 oct. 2020 08h05 HE | InCarda Therapeutics, Inc.
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for...
22157.jpg
North America Implantable Loop Recorders Market Report 2020 Featuring Medtronic, Abbott Laboratories, Boston Scientific, BIOTRONIK SE & Co, Angel Medical Systems, Vectorious Medical Technologies
21 sept. 2020 05h08 HE | Research and Markets
Dublin, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The "North America Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals,...
CoreMap-Logo-Vertical-FullColor.png
CoreMap Completes $10.5 Million Series A Financing
16 sept. 2020 08h00 HE | CoreMap, Inc.
BURLINGTON, Vt., Sept. 16, 2020 (GLOBE NEWSWIRE) -- CoreMap announced today it has completed a $10.5 million Series A financing led by Qure Ventures. The round included both existing investors such...
CoreMap-Logo-Vertical-FullColor.png
CoreMap Wins National Science Foundation Phase I SBIR Award
08 sept. 2020 11h52 HE | CoreMap, Inc.
BURLINGTON, Vt., Sept. 08, 2020 (GLOBE NEWSWIRE) -- CoreMap, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Science...
22157.jpg
$1.3 Billion AI in Diagnostics Industry Assessment 2020-2026 by Diagnosis Type, Component and Region
26 août 2020 08h21 HE | Research and Markets
Dublin, Aug. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Artificial Intelligence in Diagnostics Market By Diagnosis Type (Radiology, Oncology, Neurology, Cardiology, Chest & Lungs, Pathology and...
22157.jpg
World Implantable Loop Recorders Market 2020-2026 - Regional Insights Into Atrial Fibrillation, Cardiac Arrhythmia, and Cardiac Syncope Applications by End-user
26 août 2020 08h08 HE | Research and Markets
Dublin, Aug. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals, Cardiac...
MyoKardia_Logo_RGB.png
MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure
22 juin 2020 08h00 HE | MyoKardia, Inc.
Danicamtiv was Well Tolerated; Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction New...
_DXT9561-M Bristow
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions
07 mai 2020 08h30 HE | ARCA biopharma, Inc.
New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence °  26% reduction in total time spent...
_DXT9561-M Bristow
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
06 mai 2020 16h30 HE | ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...